ABSTRACT
Interleukin (IL)-33 is a member of the interleukin (IL)-1 family of cytokines linked to the development of inflammatory conditions and cancer in the gastrointestinal tract. This study is designed to investigate whether IL-33 has a direct effect on human gastric epithelial cells (GES-1), the human gastric adenocarcinoma cell line (AGS), and the gastric carcinoma cell line (NCI-N87) by assessing its role in the regulation of cell proliferation, migration, cell cycle, and apoptosis. Cell cycle regulation was also determined in ex vivo gastric cancer samples obtained during endoscopy and surgical procedures. Cell lines and tissue samples underwent stimulation with rhIL-33. Proliferation was assessed by XTT and CFSE assays, migration by wound healing assay, and apoptosis by caspase 3/7 activity assay and annexin V assay. Cell cycle was analyzed by means of propidium iodine assay, and gene expression regulation was assessed by RT-PCR profiling. We found that IL-33 has an antiproliferative and proapoptotic effect on cancer cell lines, and it can stimulate proliferation and reduce apoptosis in normal epithelial cell lines. These effects were also confirmed by the analysis of cell cycle gene expression, which showed a reduced expression of pro-proliferative genes in cancer cells, particularly in genes involved in G0/G1 and G2/M checkpoints. These results were confirmed by gene expression analysis on bioptic and surgical specimens. The aforementioned results indicate that IL-33 may be involved in cell proliferation in an environment- and cell-type-dependent manner.
Subject(s)
Cell Proliferation/drug effects , Epithelial Cells/drug effects , Interleukin-33/pharmacology , Recombinant Proteins/pharmacology , Stomach Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Apoptosis/drug effects , Caspase 3/metabolism , Caspase 7/metabolism , Cell Cycle Checkpoints/drug effects , Cell Cycle Checkpoints/genetics , Cell Line , Cell Line, Tumor , Epithelial Cells/metabolism , Female , Gene Expression Regulation/drug effects , Humans , Interleukin-33/genetics , Male , Middle Aged , Stomach Neoplasms/genetics , Stomach Neoplasms/pathologySubject(s)
COVID-19/blood , Vitamin B 12/blood , Aged , Aged, 80 and over , COVID-19/mortality , COVID-19/therapy , Female , Folic Acid/blood , Humans , Intensive Care Units , Male , Middle Aged , Pneumonia, Viral/blood , Prospective Studies , SARS-CoV-2 , Vitamin B 12/administration & dosage , Vitamin B 12 Deficiency/blood , Vitamin B 12 Deficiency/epidemiologyABSTRACT
Accumulating evidence suggests that Interleukin-33 (IL-33), a member of the IL-1 family, has crucial roles in tissue homeostasis and repair, type 2 immunity, inflammation, and viral infection. IL-33 is a novel contributing factor in tumorigenesis and plays a critical role in regulating angiogenesis and cancer progression in a variety of human cancers. The partially unraveled role of IL-33/ST2 signaling in gastrointestinal tract cancers is being investigated through the analysis of patients' samples and by studies in murine and rat models. In this review, we discuss the basic biology and mechanisms of release of the IL-33 protein and its involvement in gastrointestinal cancer onset and progression.